Infectious disease
It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look.
A multi-institutional research team has developed a nasal spray that effectively blocks absorption of the SARS-CoV-2 virus in ferrets with direct contact to infected animals.
There was a handful of positive clinical trial news reported today. Here’s a look.
Harvard immunology experts comment on studies regarding antibodies in COVID-19 patients diminishing over time.
When it comes to a novel virus like SARS-CoV2, a certain amount of “rolling with the punches” is required, and governments and global organizations like the World Health Organization are beginning to dismiss certain treatments and devote themselves wholeheartedly to others.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The Oxford and AstraZeneca co-developed COVID-19 vaccine could be one of the first vaccines submitted for regulatory approval, alongside Pfizer and BioNTech’s vaccine candidate BNT162b2.
Remdesivir brought in $873 million in the third quarter, the first full quarter the drug has been on the market. But the drug is facing a storm of controversy.
The COVID-19 pandemic changed the biopharma industry and the world irrevocably. The challenges will reverberate even after the pandemic ends, according to panelists at the Cell and Gene Meeting on the Mesa in mid-October.
Researchers are generating an unprecedented amount of data around COVID-19, with seemingly new and important studies coming out every day. Here’s a look at some of this week’s COVID-19 research news.
PRESS RELEASES